Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 15/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | PTGES | O14684 | 3/20 | 0.65 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.65 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278905 | 0.85 | TAS2R14 (0.80) | TAS2R14PTGESCXCR3TAS2R8 | |
| SCHEMBL407669 | 0.85 | ALDH1A1 (0.73) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1278616 | 0.84 | TAS2R14 (1.00) | TAS2R14MEN1KMT2APTGESCXCR3 | |
| SCHEMBL10909120 | 0.84 | ALDH1A1 (0.68) | TAS2R14MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5450808 | 0.83 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1278788 | 0.83 | TAS2R14 (0.97) | TAS2R14MEN1KMT2APTGESCXCR3 | |
| SCHEMBL3877799 | 0.82 | HSD17B1 (0.65) | TAS2R14MEN1KMT2APTGESALDH1A1 | |
| SCHEMBL14470257 | 0.82 | ALDH1A1 (0.69) | TAS2R14MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL14470114 | 0.81 | KMT2A (0.70) | TAS2R14MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4236580 | 0.81 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | disclosed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9247759-B2 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-7939671-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939671-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939671-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009025793-A2 | HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF | SENOMYX, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | TAS2R50, TAS2R1, TAS2R30 | TAS2R14 28/4885MEN1 2114/4885KMT2A 3206/4885 |
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | TAS2R14 1933/4885MEN1 4067/4885KMT2A 2996/4885 |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | TAS2R50, TAS2R1, TAS2R30 | TAS2R14 28/4885MEN1 2097/4885KMT2A 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.